PACS Group (NYSE: PACS - Get Free Report) and iSpecimen (NASDAQ: ISPC - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings. Valuation and Earnings This table compares PACS Group and

PACS Group, Inc. (NYSE: PACS - Get Free Report) has been given an average recommendation of "Hold" by the five research firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the

Evelyn Dilsaver acquired $500,000 worth of PACS Group Stock. Dilsaver is a member of Pacs Group's Board of Directors.

FARMINGTON, Utah--(BUSINESS WIRE)--PACS Group, Inc. (NYSE: PACS) (“PACS” or the “Company”), which together with its subsidiaries is one of the largest post-acute healthcare companies in the United States, announces the appointments of Kelly Priegnitz as Chief Compliance Officer and Trent Bingham as Chief Human Resources Officer. Mr. Bingham joined PACS on Nov. 10, while Ms. Priegnitz began her role on Dec. 1. Ms. Priegnitz joins PACS after serving as Executive Vice President and Chief Legal and.

Amarantus Bioscience (OTCMKTS:AMBS - Get Free Report) and PACS Group (NYSE: PACS - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, analyst recommendations, earnings and institutional ownership. Analyst Ratings This is a summary of recent

FARMINGTON, Utah--(BUSINESS WIRE)--PACS Group, Inc. (NYSE: PACS) (“PACS” or the “Company”), which together with its subsidiaries is one of the largest post-acute healthcare companies in the United States, announced several business updates that build on the Company's momentum and strong year-to-date operational and financial performance. “The amendment and waiver to our credit agreement and the latest addition to our growing portfolio demonstrate how our team continues to execute on our strateg.

Markets were broadly lower on Thursday, giving up early gains as excitement about Nvidia's latest financial results gave way to worries about the future. PACS Group and Exact Sciences led gainers on the day.

PACS Group, Inc. ( PACS ) Q3 2025 Earnings Call November 19, 2025 5:30 PM EST Company Participants Mark Hancock - Co-Founder, Interim CFO & Executive Vice Chairman Jason Murray - Co-Founder, CEO & Chairman Joshua Jergensen - President & COO Conference Call Participants David MacDonald - Truist Securities, Inc., Research Division Benjamin Rossi - JPMorgan Chase & Co, Research Division Benjamin Hendrix - RBC Capital Markets, Research Division Presentation Operator Hello, and welcome to PACS Group's Third Quarter 2025 Earnings Conference Call. [Operator Instructions] The speakers on today's call are PACS Group's Chief Executive Officer, Jason Murray; Mark Hancock, Interim Chief Financial Officer; and Josh Jergensen, President and Chief Operating Officer.

FARMINGTON, Utah--(BUSINESS WIRE)--PACS announced operating results for the third quarter of 2025. PACS has completed its Restatement of financials and is current with SEC obligations.

FARMINGTON, Utah--(BUSINESS WIRE)--PACS will release its third quarter 2025 earnings and file its outstanding annual and quarterly filings through Sept 30, 2025 on Weds, Nov 19, 2025.